Printer Friendly

DISEASE DETECTION INTERNATIONAL INC. SIGNS DISTRIBUTION AGREEMENTS WITH BAXTER'S SCIENTIFIC PRODUCTS DIVISION FOR ONE-STEP PREGNANCY TEST

 IRVINE, Calif., Sept. 7 /PRNewswire/ -- Disease Detection International Inc. (NASD OTC Bulletin Board: DDII) ("DDI"), announced today the company has signed a Distribution Agreement with Baxter Diagnostics' Scientific Products Division to sell the Company's Pro- Step-hCG(TM) one-step pregnancy test into the hospital clinical lab market. Baxter is the world's largest supplier of medical products and will launch DDI's new three-minute, single-step test beginning in September.
 H. Thad Morris, DDI's president and chief executive officer, stated "Baxter represents a significant opportunity for the company to compete in a major segment of the health care industry. While we have enjoyed a successful launch of this unique product in the physician's office markets and will reach the consumer market through our women's health care company, FHC Corp., we were lacking a major presence in the more than 5,000 hospital and reference laboratories. Baxter's more than 250 clinical laboratory sales representatives and preferred vendor status with major hospital purchasing organizations could add significant revenues for the company." While Baxter sells competing products, the Pro-Step hCG(TM) one-step, three-minute test is one of only three or four pregnancy tests made in the United States which can be performed on a serum or urine specimen. Many competing products can use only urine as a specimen or only serum as a specimen and the hospital is forced to purchase a separate test kit for each specimen, adding to the high cost of inventory management.
 DDI's one-step, three-minute test is of particular value in a hospital setting due to its ability to detect pregnancy three or four days prior to a missed period. The ability to detect pregnancy at such an early stage can impact medical decisions as to medication and X-ray therapy that may not be administered in light of the knowledge of conception.
 Mr. Morris commented, "We are pleased to join with Baxter in launching this test into the hospital market. The Baxter Agreement rounds out our coverage in each segment of the U.S.A. pregnancy business. With more than 300 representatives already selling into the physician's office market and a similar number detailing in the retail, over-the-counter (OTC) market, we will concentrate our efforts on additional test development to feed through our distribution system."
 Disease Detection International Inc., develops, manufactures and markets a family of patented, easy-to-use, rapid, diagnostic test kits to aid in the diagnosis of infectious diseases and pregnancy testing.
 -0- 9/7/93
 /CONTACT: H. Thad Morris, 714-457-1787/
 (DDII)


CO: Disease Detection International Inc. ST: California IN: MTC SU: JVN

EH -- LA013 -- 9220 09/07/93 09:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 7, 1993
Words:430
Previous Article:ALBARA CORP. REPORTS SUBSIDIARY FILES CHAPTER 11
Next Article:RANGER OIL LIMITED ISSUES SENIOR NOTES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters